Opendata, web and dolomites

Vacc-iNTS SIGNED

Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africa

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Vacc-iNTS project word cloud

Explore the words cloud of the Vacc-iNTS project. It provides you a very rough idea of what is the project "Vacc-iNTS" about.

shigella    tackling    experts    strains    rapid    healthy    collaborative    endemic    bridges    deployment    academia    typhimurium    followed    roadblocks    fatality    released    rate    drive    gmma    limited    advocacy    generate    trial    resistance    epidemiological    modified    antibodies    gap    integration    resource    data    immunogenic    countries    preclinical    levels    stage    transcriptomics    enteritidis    antibiotic    scalable    ints    antibody    generalized    lt    lots    immunogenicity    profit    20    manufacturing    proposes    biology    serum    blebs    serotypes    antigens    bacteria    adults    poor    settings    bactericidal    vacc    africa    olds    infectious    proof    safety    typhoidal    advancing    african    vaccine    network    sub    industry    cellular    clinical    salmonellosis    advocate    sonnei    sero    gmp    accelerate    membrane    ssa    animals    invasive    difficult    outer    deaths    saharan    genetically    diagnosis    disease    modules    strengthen    trials    suited    263   

Project "Vacc-iNTS" data sheet

The following table provides information about the project.

Coordinator
SCLAVO VACCINES ASSOCIATION 

Organization address
address: PIAZZA LA LIZZA 7
city: SIENA
postcode: 53100
website: www.sclavo.org/home

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 0 €
 EC max contribution 6˙871˙188 € (0%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Two-Stage-RTD
 Funding Scheme RIA-LS
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2024-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SCLAVO VACCINES ASSOCIATION IT (SIENA) coordinator 1˙152˙311.00
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 2˙227˙288.00
3    GSK VACCINES INSTITUTE FOR GLOBAL HEALTH SRL IT (SIENA) participant 1˙576˙515.00
4    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 545˙942.00
5    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 432˙034.00
6    UNIVERSITA DEGLI STUDI DI SIENA IT (SIENA) participant 341˙017.00
7    KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY KUMASI GH (KUMASI) participant 194˙226.00
8    UNIVERSITE OUAGA I PROFESSEUR JOSEPH KI-ZERBO BF (OUAGADOUGOU 03) participant 192˙980.00
9    KENYA MEDICAL RESEARCH INSTITUTE KE (Nairobi) participant 107˙575.00
10    UNIVERSITY OF OTAGO NZ (DUNEDIN) participant 50˙000.00
11    PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE BE (ANTWERPEN) participant 31˙296.00
12    MMGH CONSULTING GMBH CH (ZURICH) participant 20˙000.00

Map

 Project objective

Invasive non-typhoidal Salmonellosis (iNTS) is an important emerging Neglected Infectious Disease in resource-poor settings of sub-Saharan Africa (sSA). No vaccine is currently available. Estimated 263,000 iNTS deaths per year in <5 year olds, a 20% case fatality rate, difficult diagnosis and increasing antibiotic resistance strongly advocate for rapid development of an effective vaccine. Vacc-iNTS bridges the gap between preclinical and early clinical development of a novel vaccine against iNTS, based on GMMA (Generalized Modules for Membrane Antigens) from the most common African iNTS serotypes (Typhimurium and Enteritidis). The highly cost-effective GMMA-technology, developed by partner 2, is based on outer membrane blebs released by genetically modified bacteria. Clinical proof-of-concept for the GMMA-technology was achieved with a Shigella sonnei vaccine in European and African adults. In animals, iNTS-GMMA were highly immunogenic and induced antibodies with bactericidal activity against African iNTS strains. Simple, robust and scalable manufacturing processes for iNTS-GMMA, suited for sSA, have been developed. Vacc-iNTS proposes GMP manufacturing of clinical lots followed by a two-stage Phase 1 trial in healthy European and African adults to investigate safety and immunogenicity of the iNTS-GMMA vaccine. Analysis include serum antibody levels and functionality, cellular responses, transcriptomics and data integration through a systems biology approach. Sero-epidemiological analysis will be conducted to provide essential data for future Phase 2 and 3 trials. Vacc-iNTS will also strengthen a collaborative network of iNTS experts from academia, industry and non-profit including partners from disease-endemic countries of sSA. The network will generate data to accelerate further vaccine development, enhance awareness, drive advocacy and vaccine deployment in limited-resources disease-endemic countries, tackling major roadblocks in advancing a vaccine against iNTS.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VACC-INTS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VACC-INTS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More